Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02755896 · ClinicalTrials.gov registry record · Phase 2
Trial to Compare Radiation Fibrosis With Five Versus Three Fractions
A Phase 2 study of Malignant Neoplasm of Breast Stage I, sponsored by Weill Medical College of Cornell University.
- Active
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
- 4
- Study locations
NCT02755896 is a Phase 2 study of Malignant Neoplasm of Breast Stage I that is active but no longer recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 350 participants. The trial reports 4 study locations across 2 states.
The verdict
NCT02755896, a Phase 2 study of Malignant Neoplasm of Breast Stage I, is active but no longer recruiting, sponsored by Weill Medical College of Cornell University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
- 4
- Study locations
Study Summary
Post meno-pausal women with T1 Breast cancers will be randomized to receive either 600 centiGray (cGy) X 5 over five consecutive days (arm 1) versus 800 cGy X 3 fractions given every other day (arm 2). Patients will complete treatment in one week. All patients will be followed a month after the completion of treatment then q6 months for the first year, then yearly for the next 10 years.
Conditions Studied
Interventions
- RADIATION Arm 1 600 cGY x 5 fractions
- RADIATION Arm 2 800 cGY x 3 fractions
Study Locations (4)
New York
- Weill Cornell Medical College - New York
- Brooklyn Methodist Hospital - NewYork Presbyterian - New York
- New York Presbyterian Hospital - Queens - New York
California
- University of Southern California - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2015-10-14 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02755896
The ClinicalTrials.gov registry entry for NCT02755896 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Neoplasm of Breast Stage I appearing as the primary indexed condition, and to 2 interventions - of which Arm 1 600 cGY x 5 fractions is the first listed.
NCT02755896 reports 4 study locations spanning 2 distinct geographic areas - top geographies include New York, California.
Frequently Asked Questions
What is clinical trial NCT02755896 about?
NCT02755896 is a clinical study titled "Trial to Compare Radiation Fibrosis With Five Versus Three Fractions". Post meno-pausal women with T1 Breast cancers will be randomized to receive either 600 centiGray (cGy) X 5 over five consecutive days (arm 1) versus 800 cGy X 3 fractions given every other day (arm 2). Patients will complete treatment in one week. All patients will be followed a month after the comp...
What is the current status of trial NCT02755896?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2015-10-14. Estimated completion is 2027-12.
What conditions does trial NCT02755896 study?
This clinical trial studies the following conditions: Malignant Neoplasm of Breast Stage I.
What interventions are being tested in trial NCT02755896?
The interventions under investigation include: Arm 1 600 cGY x 5 fractions (RADIATION), Arm 2 800 cGY x 3 fractions (RADIATION).
Who is sponsoring clinical trial NCT02755896?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02755896 being conducted?
This trial has 4 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.